Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII.

PubWeight™: 1.75‹?› | Rank: Top 3%

🔗 View Article (PMID 12663706)

Published in J Clin Oncol on April 01, 2003

Authors

A Wallgren1, M Bonetti, R D Gelber, A Goldhirsch, M Castiglione-Gertsch, S B Holmberg, J Lindtner, B Thürlimann, M Fey, I D Werner, J F Forbes, K Price, A S Coates, J Collins, International Breast Cancer Study Group Trials I through VII

Author Affiliations

1: University of Göteborg, Sahlgrenska University Hospital, Göteborg, Sweden. arne.wallgren@oncology.gu.se

Articles citing this

Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol (2012) 4.33

Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a prospective randomized trial evaluating chemotherapy after local therapy for isolated locoregional recurrences of breast cancer. Ann Surg Oncol (2008) 1.48

Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy. CMAJ (2004) 1.46

The 21-gene recurrence score and locoregional recurrence in breast cancer patients. Ann Surg Oncol (2014) 1.40

BMI1 cooperates with H-RAS to induce an aggressive breast cancer phenotype with brain metastases. Oncogene (2009) 1.38

Deletion of PTEN promotes tumorigenic signaling, resistance to anoikis, and altered response to chemotherapeutic agents in human mammary epithelial cells. Cancer Res (2009) 1.29

Tumour dormancy in breast cancer: an update. Breast Cancer Res (2007) 1.23

Lymph node ratio is more valuable than level III involvement for prediction of outcome in node-positive breast carcinoma patients. World J Surg (2007) 1.00

Present-day locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy. Ann Surg Oncol (2010) 0.92

Locoregional recurrence risk factors in breast cancer patients with positive axillary lymph nodes and the impact of postmastectomy radiotherapy. Int J Clin Oncol (2011) 0.92

Postmastectomy radiation therapy: an overview for the practicing surgeon. ISRN Surg (2013) 0.91

A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype. Breast Cancer Res (2014) 0.90

Treatment results of breast cancer patients with locoregional recurrence after mastectomy. Radiat Oncol J (2013) 0.89

Patterns and risk factors of locoregional recurrence in T1-T2 node negative breast cancer patients treated with mastectomy: implications for postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys (2011) 0.89

Post-mastectomy radiotherapy benefits subgroups of breast cancer patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis. Radiol Oncol (2014) 0.88

The prognostic value of the nodal ratio in N1 breast cancer. Radiat Oncol (2011) 0.88

Which patients might benefit from postmastectomy radiotherapy in breast cancer patients with t1-2 tumor and 1-3 axillary lymph nodes metastasis? Cancer Res Treat (2013) 0.87

Breast cancer local recurrence: risk factors and prognostic relevance of early time to recurrence. World J Surg (2007) 0.86

Identification of Risk Factors for Locoregional Recurrence in Breast Cancer Patients with Nodal Stage N0 and N1: Who Could Benefit from Post-Mastectomy Radiotherapy? PLoS One (2015) 0.83

Prognostic factors affecting locoregional recurrence in patients with stage IIIB noninflammatory breast cancer. World J Surg (2007) 0.81

Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report. Ann Oncol (2012) 0.81

Design and in vitro evaluation of layer by layer siRNA nanovectors targeting breast tumor initiating cells. PLoS One (2014) 0.80

Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer. Ann Oncol (2008) 0.80

Current indications for post-mastectomy radiation. Int Semin Surg Oncol (2009) 0.78

Real-world outcomes of postmastectomy radiotherapy in breast cancer patients with 1-3 positive lymph nodes: a retrospective study. J Radiat Res (2013) 0.78

The importance of systemic therapy in minimizing local recurrence after breast-conserving surgery: the NSABP experience. J Surg Oncol (2014) 0.78

(18)F-FDG/PET May Help to Identify a Subgroup of Patients with T1-T2 Breast Cancer and 1-3 Positive Lymph Nodes Who Are at a High Risk of Recurrence after Mastectomy. Cancer Res Treat (2015) 0.77

Body mass index and treatment outcomes following neoadjuvant therapy in women aged 45 y or younger: Evidence from a historic cohort. Cancer Biol Ther (2016) 0.77

Managing breast cancer in younger women: challenges and solutions. Breast Cancer (Dove Med Press) (2015) 0.76

Time to breast cancer relapse predicted by primary tumour characteristics, not lymph node involvement. World J Surg (2014) 0.76

Breast cancer local therapy: what is its effect on mortality? World J Surg (2012) 0.76

A prognostic index for locoregional recurrence after neoadjuvant chemotherapy. Ecancermedicalscience (2016) 0.75

Relapse profile of early breast cancer according to immunohistochemical subtypes: guidance for patient's follow up? Ther Adv Med Oncol (2015) 0.75

Role of postmastectomy radiation therapy in breast cancer patients with T1-2 and 1-3 positive lymph nodes. Onco Targets Ther (2016) 0.75

Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. Ann Surg Oncol (2016) 0.75

Prognostic Factors for Distant Metastasis in Patients with Locoregional Recurrence after Mastectomy. J Breast Cancer (2015) 0.75

Locoregional and Distant Recurrence Patterns in Young versus Elderly Women Treated for Breast Cancer. Int J Breast Cancer (2015) 0.75

Possible benefits from post-mastectomy radiotherapy in node-negative breast cancer patients: a multicenter analysis in Korea (KROG 14-22). Oncotarget (2017) 0.75

Are there patients with T1 to T2, lymph node-negative breast cancer who are "high-risk" for locoregional disease recurrence? Cancer (2017) 0.75

Articles by these authors

A small cosmid for efficient cloning of large DNA fragments. Gene (1980) 22.61

Cosmids: a type of plasmid gene-cloning vector that is packageable in vitro in bacteriophage lambda heads. Proc Natl Acad Sci U S A (1978) 16.33

Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol (2011) 13.95

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet (2005) 11.05

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol (2013) 9.68

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol (2009) 9.18

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet (2007) 8.08

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol (2007) 7.33

Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet (2005) 7.25

Analysis of survival by tumor response. J Clin Oncol (1983) 5.91

Quality and the use of time in general practice: widening the discussion. BMJ (1989) 5.59

Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol (2005) 5.41

Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol (2001) 5.31

Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med (1991) 5.22

Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst (1997) 4.60

School-based programs to reduce sexual risk behaviors: a review of effectiveness. Public Health Rep (1994) 4.50

Redressing the balance--the ethics of not entering an eligible patient on a randomised clinical trial. Ann Oncol (1992) 4.41

Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol (2002) 4.32

Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med (1995) 4.03

Periodontal infection as a possible risk factor for preterm low birth weight. J Periodontol (1996) 4.02

Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood (2001) 3.93

Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet (2000) 3.79

Plasmids useable as gene-cloning vectors in an in vitro packaging by coliphage lambda: "cosmids". Gene (1978) 3.66

Characterization of mouse monoclonal antibodies specific for Friend murine leukemia virus-induced erythroleukemia cells: friend-specific and FMR-specific antigens. Virology (1981) 3.61

Cloning of the complete human cytomegalovirus genome in cosmids. Gene (1982) 3.55

Randomised comparison of procedures for obtaining informed consent in clinical trials of treatment for cancer. Br Med J (Clin Res Ed) (1986) 3.52

Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst (1998) 3.50

Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet (1999) 3.50

Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J Biol Chem (1999) 3.35

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol (2000) 3.33

Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol (1996) 3.30

Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol (2001) 3.29

Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol (2004) 3.29

Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood (2001) 3.24

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol (1992) 3.17

Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer (1998) 3.03

Activation of a transposable element in the germ line but not the soma of Caenorhabditis elegans. Nature (1987) 3.00

Gonadotrophin stimulation test ovarian function. Br Med J (1968) 2.99

A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood (1999) 2.98

Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet (2008) 2.91

Organization and function of an accident flying squad. Br Med J (1966) 2.88

Instability of palindromic DNA in Escherichia coli. Cold Spring Harb Symp Quant Biol (1981) 2.75

Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol (2006) 2.72

Randomized comparison of reduction and fixation, bipolar hemiarthroplasty, and total hip arthroplasty. Treatment of displaced intracapsular hip fractures in healthy older patients. J Bone Joint Surg Am (2006) 2.71

Escherichia coli plasmids packageable in vitro in lambda bacteriophage particles. Methods Enzymol (1979) 2.71

Fertility and ageing. Hum Reprod Update (2005) 2.68

Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group. J Clin Oncol (1992) 2.67

Changing character of cervical cancer in young women. BMJ (1989) 2.66

Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol (2001) 2.59

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer (2001) 2.58

Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. J Clin Oncol (1989) 2.57

Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol (2001) 2.37

Sequence interruptions in enterobacterial repeated elements retain their ability to encode well-folded RNA secondary structures. Mol Microbiol (1997) 2.33

Free ribosomal DNA molecules from Tetrahymena pyriformis GL are giant palindromes. J Mol Biol (1976) 2.33

Who gets chemotherapy for metastatic lung cancer? Chest (2000) 2.27